Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | CBL |
| Variant | act mut |
| Impact List | unknown |
| Protein Effect | gain of function |
| Gene Variant Descriptions | CBL act mut indicates that this variant results in a gain of function in the Cbl protein. However, the specific amino acid change has not been identified. |
| Associated Drug Resistance | |
| Category Variants Paths |
CBL mutant CBL act mut |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04487106 | Phase II | Azacitidine + Trametinib + Venetoclax | Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | Completed | USA | 0 |
| NCT07032727 | Phase II | Olutasidenib + Ruxolitinib Gilteritinib + Olutasidenib + Venetoclax Gilteritinib + Olutasidenib Cladribine + Cytarabine + Olutasidenib + Venetoclax Cladribine + Cytarabine + Olutasidenib | Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations | Recruiting | USA | 0 |
| NCT05658640 | Phase Ib/II | Cyclophosphamide + Cytarabine + Dexamethasone + Trametinib | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies (HEM-iSMART D) | Recruiting | SWE | NOR | NLD | ITA | ISR | IRL | GBR | FRA | FIN | ESP | DNK | DEU | CHE | BEL | AUT | 0 |